April 03, 2025

Depemokimab Reduces Nasal Polyps, Obstruction in CRSwNP

Depemokimab significantly reduced nasal polyp scores and obstruction symptoms in patients with chronic rhinosinusitis in the ANCHOR-1 and ANCHOR-2 trials. The data support depemokimab as a twice-yearly treatment option, researchers reported.

Conexiant

April 03, 2025

Patterns in Adherence to USPSTF Lung Cancer Screening Guidelines

In a study reported as a research letter in JAMA Oncology, Rolle et al found increased overall adherence to the 2021 updated U.S. Preventive Services Task Force (USPSTF) lung cancer screening guidelin...

The ASCO Post

April 03, 2025

Youth Vaping: Comparable to Traditional Smoking, Study

Findings suggest that nicotine intake is similar among adolescents who vape and adolescents who smoke, highlighting critical implications for addiction.

Conexiant

April 03, 2025

Pulmonary Embolism in ESKD: New Data on Risk, Outcomes

Fewer than half of patients with end-stage kidney disease who survived pulmonary embolism filled an anticoagulation prescription, yet PE recurrence rates were similar between those who did and did not receive anticoagulation (4.2% vs. 2.8%; P = .11), according to a new study.

Conexiant

April 03, 2025

Study Reveals Psychiatric Sequelae Post-COVID-19

COVID-19 survivors showed a significantly higher risk of psychiatric disorders, according to a recent study.

Conexiant

April 03, 2025

Lung Screening Lags Despite Cancer Prevention Uptake

Eligible patients undergo breast and colorectal cancer screenings at nearly four times the rate of recommended lung cancer screening, revealing significant intervention opportunities, according to a new JAMA study.

Conexiant

April 02, 2025

New Antibody Lowers COVID-19 Cases in Trial

Sipavibart reduced symptomatic COVID-19 by 34.9% compared to standard treatment, but efficacy was only observed against non–Phe456Leu-containing variants, according to new phase 3 trial data.

Conexiant

April 02, 2025

FDA Misses Novavax Decision Date

FDA misses April 1 deadline for deciding on Novavax's COVID-19 vaccine.

Reuters

April 02, 2025

FDA Approves Automated Latent TB Test

Revvity’s Auto-Pure 2400 platform for use with the T-SPOT.TB test to automate latent tuberculosis diagnostics was approved by the FDA.

Conexiant